Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis: Experience of a fourth level center
PDF (Español)

Keywords

Vasculitis
Anti-neutrophil cytoplasmic antibody
mortality
renal failure
survival

How to Cite

1.
Hurtado-Uriarte M, Chavarro-Alfonso OJ, Ramírez-Jiménez SX, Vargas-Brochero MJ, Mora-Méndez JM. Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis: Experience of a fourth level center . Rev. Colomb. Nefrol. [Internet]. 2024 Jan. 31 [cited 2024 Jul. 18];11(1). Available from: https://revistanefrologia.org/index.php/rcn/article/view/713

Abstract

Introduction: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis affects small vessels. There are few reports in hospitalized patients. The objective of the study was to describe the demographic, clinical-pathological characteristics, complications, relapses and outcomes.

Purpose: To describe the experience in the diagnosis, management and outcome of this pathology during 6 years.

Methodology: Retrospective cross-sectional descriptive study. Non-probability sampling for convenience developed at the Hospital Clínica San Rafael Bogotá Colombia between 2017-2022.

Results: 23 patients were included. 60.9% men with a mean age of 50 years. The main symptom was hemoptysis (21.7%). 47.6% behaved like rapidly progressive glomerulonephritis and 21.7% presented lung involvement. The positivity of pANCAS, cANCAS, ANAS, Anti MPO and AntiPR3 was 73.9%, 13%, 47.6%, 31.6% and 8.3% respectively. Biopsy was performed in 21 patients with an average of 22 glomeruli documenting 70% pauciimmune pattern. Plasma exchange was performed in 73.9% and the most widely used regimen was CYCLOPS (78.3%). No patient died. 73.9% required dialysis of which 60.9% discharged on dialysis. Renal function recovery was observed at 6 and 12 months in 21.7% and 26.1%. The relapse at one year occurred in 27.3%.

Conclusions: It is essential to know the clinical manifestations, diagnostic tests and treatment of this entity, especially because if it is carried out effectively, mortality and complications can be modified. Patients who received timely treatment presented a high percentage of renal recovery despite the severe compromise in the renal biopsy.

https://doi.org/10.22265/acnef.11.1.713
PDF (Español)

References

Jarrot PA, Kaplanski G. Pathogenesis of ANCA-associated vasculitis: An update. Autoimmunity Reviews. 2016 jul.;15(7):704-13.

https://doi.org/10.1016/j.autrev.2016.03.007

Jennette JC, Nachman PH. ANCA Glomerulonephritis and vasculitis. Clin J Am Soc Nephrol. 2017 oct.; 12(10):1680-91.

https://doi.org/10.2215/CJN.02500317

Okazaki T, Shinagawa S, Mikage H. Vasculitis syndrome-diagnosis and therapy. J Gen Fam Med. 2017 mar.;18(2):72-8.

https://doi.org/10.1002/jgf2.4

Cornec D, Cornec-Le Gall E, Fervenza FC, Specks U. ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol. 2016 oct;12(10):570-9.

https://doi.org/10.1038/nrrheum.2016.123

Houben E, Bax WA, van Dam B, Slieker WAT, Verhave G, Frerichs FCP, et al. Diagnosing ANCA-associated vasculitis in ANCA positive patients: A retrospective analysis on the role of clinical symptoms and the ANCA titre. Medicine. 2016 oct.;95(40):e5096.

https://doi.org/10.1097/MD.0000000000005096

Saffarzadeh M, Juenemann C, Queisser MA, Lochnit G, Barreto G, Galuska SP, et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: A predominant role of histones. Hartl D, editor. PLoS ONE. 2012 feb. 28;7(2):e32366.

https://doi.org/10.1371/journal.pone.0032366

Shi L. Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes. Rheumatol Int. 2017 nov.;37(11):1779-88.

https://doi.org/10.1007/s00296-017-3818-y

Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J. 1958 aug. 2;2(5091):265-70.

https://doi.org/10.1136/bmj.2.5091.265

Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. American Journal of Kidney Diseases. 2003 apr.;41(4):776-84.

https://doi.org/10.1016/S0272-6386(03)00025-8

Cantillo JJ, Andrade RE. El lado renal de la poliangeítis microscópica: A propósito de dos nuevos casos en Colombia. Acta Med Colomb. 2008;33(2):84-89. https://www.redalyc.org/pdf/1631/163113350007.pdf

Sánchez Betancourt A, González Cole M. Poliangeítis granulomatosa con eosinofilia. Revisión y reporte de caso de una paciente con eosinofilia, mononeuropatía de miembro inferior, rinosinusitis y asma. Revista Colombiana de Reumatología. 2015 sept.;22(3):180-5.

https://doi.org/10.1016/j.rcreu.2015.06.003

Córdoba JP, González C, Huérfano M, Vela F, Rodríguez P. Síndrome pulmón-riñón: serie de casos del Hospital Universitario San Ignacio. Revista Colombiana de Reumatología. 2015 mzo.;22(1):11-5.

https://doi.org/10.1016/j.rcreu.2015.02.005

Ochoa CD, Ramírez F, Quintana G, Toro C, Cañas C, Osio LF, et al. Epidemiología de las vasculitis primarias en Colombia y su relación con lo informado para Latinoamérica. Revista Colombiana de Reumatología. 2009 sept.;16(3):248-63.

https://doi.org/10.1016/S0121-8123(09)70103-3

Polanco NA, Soto-Abraham M, Vázquez Rangel A. Características clinicopatológicas de la vasculitis renal pauciinmune en México: reporte de 23 casos. Revista Colombiana de Reumatología. 2017 abr.;24(2):70-8.

https://doi.org/10.1016/j.rcreu.2017.01.001

Ramírez F, Jaramillo D, Ochoa C, Toro C, Méndez-Patarroyo P, Coral P, et al. Renal vasculitis in Colombia. Rev Colomb Nefrol. 2015 jun. 30;2(1):3-11.

https://doi.org/10.22265/acnef.2.1.192

Secretaría de Planeación Distrital. Total de población en Bogotá por localidades, 2008 - 2021. Visor de Población 2018. https://bogotacomovamos.org/datos/poblacion/

Pin-Godos MT, Hernández-Jaras J, Torregrosa-de-Juan E, Calvo-Gordo C, Pons-Prades R, García-Pérez H, et al. Análisis retrospectivo de pacientes con vasculitis sistémica generalizada y severa: experiencia de un centro. Diál traspl. 2009;30(2):42-5.

https://doi.org/10.1016/S1886-2845(09)70968-3

Córdova-Sánchez BM, Mejía-Vilet JM, Morales-Buenrostro LE, Loyola-Rodríguez G, Uribe-Uribe NO, Correa-Rotter R. Clinical presentation and outcome prediction of clinical, serological, and histopathological classification schemes in ANCA-associated vasculitis with renal involvement. Clin Rheumatol. 2016 jul.;35(7):1805-16.

https://doi.org/10.1007/s10067-016-3195-z

Jayne DR, Gaskin G, Rasmussen N, Abramowicz FF, Ferrario F, Guillevin, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18(7):2180-88.

https://doi.org/10.1681/ASN.2007010090

de Groot K, Harper L, Jayne DR, Flores Suárez LF, Gregorini G, Gross WL, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150(10):670-80. https://doi.org/10.7326/0003-4819-150-10-200905190-00004

Walsh M, Merkel PA, Peh CA, , Szpirt W, Guillevin L, Pusey CD, et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials. 2013 mar. 14;14(73). https://doi.org/10.1186/1745-6215-14-73

Walters GD, Willis NS, Craig JC. Interventions for renal vasculitis in adults. A systematic review. BMC Nephrol. 2010 jun. 24;11(12).

https://doi.org/10.1186/1471-2369-11-12

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Dimensions


PlumX


Downloads

Download data is not yet available.